BioSpace News Archive

Under the research and development agreement announced Wednesday, Viatris is securing global rights to Idorsia’s late-stage heart and lupus candidates.

Congressional legislation seeks to “equalize” the negotiating period between biologics and small molecules under the Inflation Reduction Act’s Drug Price Negotiation Program.

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced that the U.S. Food and Drug Administration cleared the Company to initiate the Phase I-IIa ArthemiR™ study of ATX-01 for the treatment of Myotonic Dystrophy Type 1.

SPT Labtech and RevoluGen Ltd. announce the successful automation of RevoluGen’s Fire Monkey™ High Molecular Weight DNA extraction chemistry in a bead-based format using SPT Labtech’s firefly® automated liquid handling platform.

Royal Philips, a global leader in health technology, announced a significant milestone as it expands access to virtually helium-free MRI to more patients in more places, with more than 1,000 systems now installed worldwide.

Akeso announced that the results of a phase II clinical trial for PD-1/CTLA-4 bispecific antibody（cadonilimab）combined with standard treatment as first-line treatment for recurrent/metastatic cervical cancer had been published in the official journal of the American Association for Cancer Research, Clinical Cancer Research, with an impact factor of 11.5.

Baird Medical Devices, Inc. announced that it is accelerating its expansion in the United States through senior hires, key partnerships, and capacity building initiatives to support its business.

Allarity Therapeutics, Inc., a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at Biomarkers 2024.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, announced that Jan De Witte has informed the Board of Directors of his intention to retire from his position as president and chief executive officer of Integra following the appointment of a successor, which the Company expects to occur by the end of 2024.

Integra LifeSciences Holdings Corporation reported financial results for the fourth quarter and full year ended December 31, 2023.